151 related articles for article (PubMed ID: 21358682)
1. G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.
Su YC; Li SC; Hsu CK; Yu CC; Lin TJ; Lee CY; Liao HF
Bone Marrow Transplant; 2012 Jan; 47(1):73-81. PubMed ID: 21358682
[TBL] [Abstract][Full Text] [Related]
2. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.
Minculescu L; Sengelov H; Marquart HV; Ryder LP; Fischer-Nielsen A; Haastrup E
Front Immunol; 2021; 12():625165. PubMed ID: 33777007
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease.
Xuan L; Wu X; Zhang Y; Fan Z; Ling Y; Huang F; Zhang F; Zhai X; Liu Q
J Transl Med; 2011 Dec; 9():215. PubMed ID: 22171570
[TBL] [Abstract][Full Text] [Related]
7. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
8. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.
Rabot M; El Costa H; Polgar B; Marie-Cardine A; Aguerre-Girr M; Barakonyi A; Valitutti S; Bensussan A; Le Bouteiller P
Int Immunol; 2007 Apr; 19(4):401-9. PubMed ID: 17307798
[TBL] [Abstract][Full Text] [Related]
9. NK Cells and PMN-MDSCs in the Graft From G-CSF Mobilized Haploidentical Donors Display Distinct Gene Expression Profiles From Those of the Non-Mobilized Counterpart.
Pelosi A; Besi F; Tumino N; Merli P; Quatrini L; Li Pira G; Algeri M; Moretta L; Vacca P
Front Immunol; 2021; 12():657329. PubMed ID: 33986748
[TBL] [Abstract][Full Text] [Related]
10. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients.
Trzonkowski P; Zaucha JM; Mysliwska J; Balon J; Szmit E; Halaburda K; Bieniaszewska M; Mlotkowska M; Hellmann A; Mysliwski A
Med Oncol; 2004; 21(1):81-94. PubMed ID: 15034218
[TBL] [Abstract][Full Text] [Related]
11. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Morris ES; MacDonald KP; Hill GR
Blood; 2006 May; 107(9):3430-5. PubMed ID: 16380448
[TBL] [Abstract][Full Text] [Related]
12. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.
Morris ES; MacDonald KP; Rowe V; Banovic T; Kuns RD; Don AL; Bofinger HM; Burman AC; Olver SD; Kienzle N; Porcelli SA; Pellicci DG; Godfrey DI; Smyth MJ; Hill GR
J Clin Invest; 2005 Nov; 115(11):3093-103. PubMed ID: 16224535
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
[TBL] [Abstract][Full Text] [Related]
14. Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.
Yu XX; Han TT; Xu LL; Chang YJ; Huang XJ; Zhao XY
J Cell Mol Med; 2018 Jun; 22(6):3025-3034. PubMed ID: 29575692
[TBL] [Abstract][Full Text] [Related]
15. Vanadium pentoxide increased PTEN and decreased SHP1 expression in NK-92MI cells, affecting PI3K-AKT-mTOR and Ras-MAPK pathways.
Gallardo-Vera F; Tapia-Rodriguez M; Diaz D; Fortoul van der Goes T; Montaño LF; Rendón-Huerta EP
J Immunotoxicol; 2018 Dec; 15(1):1-11. PubMed ID: 29228829
[TBL] [Abstract][Full Text] [Related]
16. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V
Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081
[TBL] [Abstract][Full Text] [Related]
17. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
[TBL] [Abstract][Full Text] [Related]
18. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R
J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013
[TBL] [Abstract][Full Text] [Related]
20. Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects.
Banovic T; MacDonald KP; Markey KA; Morris ES; Kuns RD; Varelias A; Hill GR
Biol Blood Marrow Transplant; 2009 Jan; 15(1):126-30. PubMed ID: 19135951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
